Innovation ETF (ARKK) Hits New 52-Week High
ARK Innovation ETF provides thematic multi-cap exposure to 'disruptive innovation.' It is an actively managed fund investing in companies that benefit from the development of new products or services, technological improvements and advancements in scientific research related to the areas of DNA technologies and genomic revolution, automation, robotics, energy storage, artificial intelligence, next-generation Internet and Fintech innovation. ARKK charges 75 bps in annual fees (see: all the Broad Developed World ETFs here).
This ETF has been an area to watch lately, given Cathie Wood's, the high-profile CEO of Ark Investment Management, explosive moves in a few stock holdings of ARKK. Cathie Wood continued its active bets on disruptive innovation by purchasing shares of CRISPR Therapeutics AG CRSP and selling 908 Devices Inc. MASS and Roku Inc. ROKU. This move reinforces ARK's long-standing bullish stance on gene-editing technologies. ARK also bought a few shares of Beam Therapeutics Inc. BEAM, reflecting evolving conviction in the future of biotech innovation. Cathie Wood remains bullish on the transformative power of emerging technologies despite the market turbulence.
ARKK might remain strong going ahead, given a weighted alpha of 60.23 and a higher 20-day volatility of 29.55%. There is definitely some promise for investors who want to ride on this surging ETF.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Beam Therapeutics Inc. (BEAM) : Free Stock Analysis Report
ARK Innovation ETF (ARKK): ETF Research Reports
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
Roku, Inc. (ROKU) : Free Stock Analysis Report
908 Devices Inc. (MASS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
42 minutes ago
- Business Insider
COIN, BMNR, RBLX: Cathie Wood Buys Over $54M of Crypto Stocks, Dumps Roblox Stake
's ARK Invest ETFs (exchange-traded funds) made aggressive moves in the crypto space on August 1, snapping up more than $54 million worth of shares in Coinbase (COIN) and Ethereum-focused company, Bitmine Immersion Technologies (BMNR). Meanwhile, Wood trimmed her positions in online gaming platform Roblox (RBLX) and biotech firm Adaptive Biotechnologies (ADPT). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Wood Doubles Down on Crypto Stocks The biggest buy of the day was Coinbase, with ARK scooping up 94,678 shares worth $35.8 million across its ARK Innovation ETF (ARKK), ARK Next Generation Internet ETF (ARKW), and ARK Fintech Innovation ETF (ARKF) funds. ARK also continued building its stake in Bitmine Immersion Technologies, purchasing 540,712 shares worth approximately $18.73 million. Like Coinbase, this investment was spread across ARKK, ARKW, and ARKF. The fund has been actively increasing its Ethereum holdings, which now exceed $2 billion, and has plans to acquire and stake up to 5% of Ethereum's total supply. BMNR stock has soared over 300% year-to-date, but Wood continues to buy aggressively on every pullback, showing strong conviction despite the sharp rally. Notably, the stock was down over 8% yesterday. Beyond crypto, ARK added 342,933 shares of Roku (ROKU) worth $32.29 million, and 162,211 shares of Illumina (ILMN) for $17.28 million. ARK Trims Stakes in RBLX and ADPT On the sell side, Wood sold a considerable portion of Roblox, offloading 353,530 shares for a total of $48.71 million. ARK Invest also trimmed its position in Adaptive Biotechnologies, selling 39,393 shares for $403,384. This follows a multi-week pattern of steady selling in the stock, reflecting either valuation concerns or a shift in ARK's genomics strategy. Let's take a brief look at how all these stocks perform on .
Yahoo
a day ago
- Yahoo
Kansas City Life: Q2 Earnings Snapshot
KANSAS CITY, Mo. (AP) — KANSAS CITY, Mo. (AP) — Kansas City Life Insurance Co. (KCLI) on Friday reported a loss of $28.1 million in its second quarter. The Kansas City, Missouri-based company said it had a loss of $2.90 per share. Earnings, adjusted for non-recurring costs, were 77 cents per share. The insurance company posted revenue of $122.3 million in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on KCLI at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
Tempus AI, Inc. TEM is scheduled to report second-quarter 2025 results on Aug. 8. In the last reported quarter, the company's adjusted loss of 24 cents was narrower than the Zacks Consensus Estimate of a loss of 27 cents per share. Tempus AI, which went public in June 2024, exceeded estimates in two of the trailing four quarters and missed in two, the average negative earnings surprise being 2.07%. The Zacks Consensus Estimate for revenues is currently pegged at $299.3 million for the second quarter, implying an 80.4% improvement over the year-ago period. The Zacks Consensus Estimate for the second-quarter bottom line has narrowed by 4 cents to a loss of 23 cents per share over the past 90 days. TEM's Earnings Estimate Revision Trend Image Source: Zacks Investment Research Throughout the second quarter of 2025, Tempus AI had an impressive run on the bourses with a 34.5% gain. Despite macroeconomic challenges, including escalating trade tensions that broadly impacted the healthcare technology sector, the company witnessed strong momentum, primarily driven by a series of strategic acquisitions and partnerships in the field of AI-driven precision medicine. During this period, the company not only surpassed the 9.3% gain posted by the broader industry but also significantly outperformed the 3.4% decline of the Medical sector. The S&P 500 benchmark index gained 10.7% during this period. The company has also outperformed other players in the health infotech field, like 10x Genomics TXG and SOPHiA GENETICS SOPH. While TXG gained 33.5%, SOPH declined 2.3% during the said period. Q2 Price Comparison Image Source: Zacks Investment Research Let's see how things have shaped up for TEM shares prior to this announcement: Key Factors to Note Prior to Tempus AI's Q2 Earnings Tempus AI recently announced a three-year, $200 million foundational model partnership with AstraZeneca AZN and Pathos, which is expected to have contributed to its second-quarter performance. This non-exclusive data licensing agreement aims to develop the world's largest foundation model in oncology using over 300 petabytes of Tempus' multimodal data. With the first version of the model expected in 9-12 months, the deal is already transforming Tempus AI's data monetization trajectory. Management confirmed that revenues from this deal will be recognized ratably over the three-year term, starting in the second quarter. Tempus AI's hereditary testing segment, which contributed meaningfully to first-quarter growth, is expected to have maintained the trend this time too. When Tempus acquired Ambry Genetics, it guided mid-to-high teens growth, but the segment exceeded expectations with a 23% unit increase. While management has been cautious about projecting ongoing acceleration, they have also expressed confidence in the long-term potential for broader hereditary screening applications, ranging from cancer to cardiovascular and neurological risk. Tempus continued to expand its diagnostics portfolio with the recent FDA clearance of ECG-Low EF, its second AI-powered ECG tool for detecting low ejection fraction, further strengthening its position in cardiology and extending its reach beyond oncology. Meanwhile, the company launched xM for TRM, a liquid biopsy assay for monitoring immunotherapy response, which showed promising early data at ASCO 2025. These likely contributed to the second-quarter top line too. Tempus AI is advancing its digital health strategy by integrating Tempus One, its GenAI clinical assistant, into EHR systems, enabling physicians to query data, access guidelines and streamline workflows. The launch of Agent Builder for custom GenAI tools further deepens its role in clinical settings. Tempus One too is expected to have witnessed strong customer adoption during the second quarter. However, despite strong top-line growth and product momentum, Tempus AI in 2025 is facing a few near-term challenges. The company remains unprofitable, with an adjusted EBITDA loss of $16.2 million in the first quarter. Though the loss narrowed year over year, it raised questions about the timeline to profitability amid ongoing R&D investments. Additionally, while the AstraZeneca-Pathos foundation model deal is significant, its revenues will be recognized ratably over three years, limiting short-term financial impact. Further, investments tied to these updates, including product development, regulatory efforts, and marketing, are likely to have pushed operating expenses higher in the second quarter, putting some pressure on short-term profitability. Broader macroeconomic factors, like tariffs, hospital budget constraints and biotech funding trends, could also affect adoption rates. Expensive Valuation TEM's stock is currently overvalued compared to its industry, as shown in the chart below. TEM is currently trading at a forward 12-month price-to-sales (P/S) ratio of 6.86, a premium to the broader industry's average of 5.80X. It also trades higher than other industry players like 10x Genomics (2.70X) and SOPHiA GENETICS (2.40X). However, the stock is trading below its one-year median of 8.00X, suggesting that it has moderated somewhat from its historical highs. Image Source: Zacks Investment Research Our Take With the AI market projected to grow exponentially in the coming years, Tempus AI is well-positioned to capitalize on expanding opportunities. With a strong financial outlook and efforts to improve healthcare outcomes, TEM presents a unique opportunity for investors seeking high returns from the AI and healthcare sectors. Yet, despite the company's several recent upsides, its premium valuation and lack of near-term profitability are limiting this Zacks Rank #3 (Hold) stock's near-term gains. While current shareholders should hold their positions, new investors should wait for the stock to retract some of its recent gains, providing a better entry point. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report 10x Genomics (TXG) : Free Stock Analysis Report SOPHiA GENETICS SA (SOPH) : Free Stock Analysis Report Tempus AI, Inc. (TEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
